Generate Biomedicines
GENB
57 hedge funds and large institutions have $1.16B invested in Generate Biomedicines in 2026 Q1 according to their latest regulatory filings, with 57 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
72.83% more ownership
Funds ownership: 0% → 72.83% (+73%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$765M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$51.5M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$48.9M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$43.9M |
| 5 |
JP Morgan Chase
New York
|
+$36M |
Top Sellers
GENB Hedge Fund Activity: Q1 2026 in Review
57 of the 8,136 institutional investors tracked by Wall St. Rank reported a position in Generate Biomedicines (GENB) for Q1 2026, worth a combined $1.16B.
Buyers outnumbered sellers: 57 funds opened new GENB positions and 0 closed out — a net gain of 57 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Flagship Pioneering, opening a new position worth an estimated $765M.
- 57 institutional investors held Generate Biomedicines (GENB) as of Q1 2026, up from 0 in Q4 2025.
- Funds reported $1.16B of Generate Biomedicines stock for Q1 2026.
- 57 funds opened new Generate Biomedicines positions in Q1 2026 and 0 closed out, a net change of +57 holders.
- The largest Generate Biomedicines buyer in Q1 2026 was Flagship Pioneering, an estimated $765M added.
Based on aggregated 13F filings for Q1 2026.